Pyrazolyl-benzoxazole derivatives as protein kinase inhibitors. Design and validation of a combinatorial library

被引:19
作者
Berta, D [1 ]
Villa, M [1 ]
Vulpetti, A [1 ]
Felder, ER [1 ]
机构
[1] Nervjano Med Sci, Dept Chem, I-20014 Nerviano, MI, Italy
关键词
solid-phase synthesis; scaffold; Mitsunobu; parallel synthesis; building blocks;
D O I
10.1016/j.tet.2005.08.070
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
The malfunctioning of protein kinases is a hallmark of numerous diseases, for which a satisfactory therapy is missing. We describe the design and synthesis of a kinase targeted library based on a novel 2-(3-phenyl-1H-pyrazol-4-yi)-1,3-benzoxazole scaffold. Ethyl 3-(3-nitrophenyl)pyrazol e-4-carboxy I ate and its 4-nitro regioisomer were bound to trityl chloride resin, saponified with NaOH in MeOH, and amidated with a choice of two o-aminophenols. The resulting N-(2-hydroxyphenyl)amides were cyclized by Mitsunobu reaction to form four variants of the pyrazolyl-benzoxazole core template. Straightforward stannous chloride reduction of the nitro group on solid phase allowed subsequent scaffold derivatization via acylation or sulfonylation of the obtained amino function. Cleavage with TFA gave rise to the final compounds (36 examples).(c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:10801 / 10810
页数:10
相关论文
共 15 条
[1]  
BERTA D, 2002, Patent No. 0262804
[2]  
Cohen MH, 2002, CLIN CANCER RES, V8, P935
[3]   Protein kinases - the major drug targets of the twenty-first century? [J].
Cohen, P .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) :309-315
[4]   A fully automated method for accurate mass determination using high-performance liquid chromatography with a quadrupole/orthogonal acceleration time-of-flight mass spectrometer [J].
Colombo, M ;
Sirtori, FR ;
Rizzo, V .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2004, 18 (04) :511-517
[5]   Protein kinases as targets for anticancer agents: from inhibitors to useful drugs [J].
Fabbro, D ;
Ruetz, S ;
Buchdunger, E ;
Cowan-Jacob, SW ;
Fendrich, G ;
Liebetanz, J ;
Mestan, J ;
O'Reilly, T ;
Traxler, P ;
Chaudhuri, B ;
Fretz, H ;
Zimmermann, J ;
Meyer, T ;
Caravatti, G ;
Furet, P ;
Manley, PW .
PHARMACOLOGY & THERAPEUTICS, 2002, 93 (2-3) :79-98
[6]  
Furet P, 2002, BIOORG MED CHEM LETT, V12, P221, DOI 10.1016/S0960-894X(01)00715-6
[7]   Imatinib mesylate (Gleevec®/Glivec®):: A new therapy for chronic myeloid leukemia and other malignancies [J].
Hernández-Boluda, JC ;
Cervantes, F .
DRUGS OF TODAY, 2002, 38 (09) :601-613
[8]   Protein kinase inhibitors as a therapeutic modality [J].
Levitzki, A .
ACCOUNTS OF CHEMICAL RESEARCH, 2003, 36 (06) :462-469
[9]   QXP: Powerful, rapid computer algorithms for structure-based drug design [J].
McMartin, C ;
Bohacek, RS .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 1997, 11 (04) :333-344
[10]   Protein kinase inhibitors: Insights into drug design from structure [J].
Noble, MEM ;
Endicott, JA ;
Johnson, LN .
SCIENCE, 2004, 303 (5665) :1800-1805